Cerebral Palsy
Cerebral Palsy
Every 20 hours, an Australian baby is born with a brain injury that underlies cerebral palsy. It is a permanent, life-long condition with no cure. Around 34,000 Australians have cerebral palsy.
What is cerebral palsy?
What are the causes of cerebral palsy?
What are the types of cerebral palsy?
What are the risk factors for cerebral palsy?
What are the symptoms of cerebral palsy?
Treatment
Our cerebral palsy research
Research into cerebral palsy prevention at Hudson Institute is multifaceted. By understanding the mechanisms involved in cerebral palsy our researchers are identifying where intervention and treatment can significantly improve wellbeing and physical outcomes for a child.
Cord blood stem cells to prevent cerebral palsy
Stem cell therapies. Babies who are born preterm are at the greatest risk of developing cerebral palsy. Professor Suzie Miller and Dr Courtney McDonald are characterising the brain injury that is most often associated with preterm birth (white matter brain injury) and examining whether cord blood stem cells can protect white matter development within the preterm brain, and in turn prevent brain injury.
Anti-inflammatory therapies for preventing brain injury
Novel treatments for neonatal seizure
Delivering neural stem cells to the developing brain
Preventing acute brain injury resultant from resuscitation of asphyxiated newborns
Reducing ventilation-induced brain injury
Cerebral Palsy collaborators
Monash Health, Monash University
Support for people with cerebral palsy
Hudson Institute scientists cannot provide medical advice.
If you would like to find out more information about cerebral palsy, please visit
Cerebral Palsy news
Explore our labs
Keep up-to-date with our latest discoveries
Molecular studies. New treatment. Too much inflammation in the brain is one of the main mechanisms that leads to the development of cerebral palsy. Dr Galinsky and his team are working on improving the understanding of how inflammation disturbs healthy brain development and developing new anti-inflammatory therapies for preventing brain injury in preterm infants.
Treatment delivery. Neural stem cells (NSCs) offer great promise as a neuroprotective therapy against a range of neurological conditions like cerebral palsy. A major challenge of NSC therapy for neurological conditions is delivering the cells to the brain. Current intracerebral delivery of NSCs is highly invasive and carries significant risks for the patient. This project is investigating the development a novel, non-invasive MRI-guided focused ultrasound (MRIgFUS) method for delivery of NSCs to the brain using a preclinical model.